{"id":1678,"date":"2009-02-01T12:06:00","date_gmt":"2009-02-01T11:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/neurontin-marketing-mit-manipulation-und-desinformation"},"modified":"2009-02-01T12:06:00","modified_gmt":"2009-02-01T11:06:00","slug":"neurontin-marketing-mit-manipulation-und-desinformation","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/neurontin-marketing-mit-manipulation-und-desinformation","title":{"rendered":"Neurontin\u00ae &#8211; Marketing mit Manipulation und Desinformation"},"content":{"rendered":"<p>In der Rubrik \u201ePerspective\u201d wird im N. Engl. J. Med. (1) die gemeinsame Marketing-Strategie der Firmen Parke-Davis, Warner-Lambert und Pfizer f\u00fcr Neurontin\u00ae (Gabapentin) geschildert. Der Blick hinter die Kulissen ist m\u00f6glich geworden, weil ein junger Mitarbeiter die Firmen darauf verklagt hat, dass sie mit falschen Behauptungen f\u00fcr nicht zugelassene Indikationen (Off-Label-Use) geworben h\u00e4tten. Es kam [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In der Rubrik \u201ePerspective\u201d wird im N. Engl. J. Med. (1) die gemeinsame Marketing-Strategie der Firmen Parke-Davis, Warner-Lambert und Pfizer f\u00fcr Neurontin\u00ae (Gabapentin) geschildert. Der Blick hinter die Kulissen ist m\u00f6glich geworden, weil ein junger Mitarbeiter die Firmen darauf verklagt hat, dass sie mit falschen Behauptungen f\u00fcr nicht zugelassene Indikationen (Off-Label-Use) geworben h\u00e4tten. Es kam [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2832,236,3824,1561],"class_list":["post-1678","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-desinformation","tag-gabapentin","tag-neurontin","tag-werbung"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1678"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1678\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}